Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Ben Bronstein is Director at Aldeyra Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Jun 11, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
1
Aldeyra TherapeuticsALDX
3 disclosures · Jun 2026
Jun 9, 202670Kdisclosed Jun 11
DetailsOfficial recordJun 9, 20265,309disclosed Jun 11
DetailsOfficial recordJun 9, 20264,977disclosed Jun 11
DetailsOfficial recordBen Bronstein bought shares on the open market in 2014, 2017 and 2019, and has not bought since 2019.
Ben Bronstein reported 3 open-market purchases and 0 sales since 2014; purchases in 3 different years, most recently 2019.
| Year | Bought | Sold |
|---|---|---|
| 2019 | $9.9K1×1 trade | — |
| 2017 | $20K1×1 trade | — |
| 2014 | $100K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Ben Bronstein bought shares on the open market in 2014, 2017 and 2019, and has not bought since 2019.
In SEC filings since 2014: the latest open-market purchase is from 2019; no open-market sale is on record.
Aldeyra Therapeutics (ALDX), from 2014 to 2019: 3 purchases and 0 sales.
Ben Bronstein reported 3 open-market purchases and 0 sales here, 2014 to 2019.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
